PHARM.AS Pharming Group (EURONEXT) 16 Jan 2026: Active at €1.60, outlook ahead
PHARM.AS stock closed the EURONEXT session on 16 Jan 2026 at €1.60, up 2.50% on volume of 13,869,887 shares. The move kept the share price above its 50-day average €1.45 and well above the 200-day average €1.12. Market participants named Pharming Group N.V. among the most active European biotech names today, driven by steady Ruconest sales and continued R&D progress. We use trading, valuation and Meyka AI model outputs to frame near-term targets and risk scenarios for investors.
PHARM.AS stock market snapshot
Pharming Group (PHARM.AS) finished the EURONEXT trading day at €1.60, with a day low of €1.56 and day high of €1.60. Volume reached 13,869,887 versus an average volume of 15,805,513, showing strong investor interest. The company’s market cap is about €1.11B and shares outstanding total 696,688,239. The stock is up 75.32% over 12 months and 9.45% year-to-date, reflecting recovery in the biotech sector and product momentum.
PHARM.AS stock trading activity and liquidity
Trading activity shows heavy turnover today but slightly below the 30-day average volume. Relative volume sits at 0.88, indicating active but not extreme intraday pressure. The 50-day average price is €1.45 and the 200-day average is €1.12, both below today’s close and supporting short-term technical strength.
High daily volume with a rising price points to accumulation rather than a sell-off. For active traders, the intraday range was narrow (€1.56–€1.60), suggesting controlled moves and limited immediate volatility despite strong momentum indicators.
PHARM.AS stock fundamentals and valuation
Pharming’s trailing EPS is -€0.01 and reported PE metrics are negative; reported PE shows -159.80 while TTM metrics list an inflated figure due to near-zero earnings. Price-to-sales is 3.48 and price-to-book is 4.58. The company’s current ratio is 3.16, and net debt is modest with debt-to-equity around 0.49, giving financial flexibility for R&D and commercial scale-up.
Revenue per share is €0.54 and free cash flow per share is €0.08, producing a free-cash-flow yield near 4.18%. These metrics place PHARM.AS above several small-cap biotech peers on valuation but below larger drugmakers on margin stability. Sector peers show average P/E near 35.38, so Pharming’s valuation requires recovery in profitability to close the gap.
PHARM.AS stock technicals and momentum
Momentum indicators show short-term strength: RSI at 71.76 (overbought) and MACD histogram positive. Bollinger Band middle is €1.45 with an upper band at €1.55, matching today’s price band. CCI at 301.75 flags overbought conditions that can lead to short consolidations.
Volume-backed momentum favors continuation while ADX at 19.35 suggests no strong trend yet. Traders should watch support at €1.45 (50-day MA) and stronger support at €1.12 (200-day MA). A daily close below €1.45 would weaken the short-term setup.
PHARM.AS stock: Meyka grade, forecast and price targets
Meyka AI rates PHARM.AS with a score out of 100: Meyka AI rates PHARM.AS with a score of 64.68 out of 100 — Grade B, Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.
Meyka AI’s forecast model projects a 12-month price of €1.93 versus the current €1.60, implying an upside of 20.48%. Monthly and quarterly estimates are €1.42 and €1.56 respectively, while three- and five-year targets are €3.02 and €4.11. Forecasts are model-based projections and not guarantees. Realistic near-term price targets: conservative €1.56–€1.80, base €1.93 (12 months), bull €3.02 (3 years), and downside support near €1.00 if product or regulatory setbacks occur.
PHARM.AS stock risks and opportunities
Opportunities include Ruconest sales growth, regulatory progress for rhC1INH and gene-therapy collaborations with partners like Novartis and Orchard Therapeutics. Continued FCF expansion and margin improvement would validate Meyka’s upside scenarios.
Risks include clinical trial outcomes, pricing pressure, and concentration in rare-disease products. High P/B and P/S ratios demand visible earnings improvement. Watch near-term catalysts such as upcoming R&D updates and the next earnings date on 12 Mar 2026 for clearer guidance.
Final Thoughts
PHARM.AS stock closed the EURONEXT session at €1.60 on 16 Jan 2026 with solid volume and short-term technical strength. Fundamentals show healthy cash coverage and manageable debt, but near-zero earnings keep PE metrics negative and valuation stretched versus large-cap healthcare peers. Meyka AI’s forecast model projects a 12-month price of €1.93, implying a 20.48% upside from today’s price, while three-year and five-year projections point to larger gains if clinical and commercial progress continues. For traders, the 50-day moving average €1.45 is a key support level; for investors, watch the 12 March 2026 earnings update and any regulatory news. These model outputs and the Meyka grade (B, HOLD) are tools to frame risk and reward, not investment advice. For live data and deeper signals, see our Meyka AI-powered market analysis page for PHARM.AS and follow sector moves in Healthcare.
FAQs
What is the current price of PHARM.AS stock?
PHARM.AS stock closed at €1.60 on 16 Jan 2026, with a day range of €1.56–€1.60 and volume 13,869,887 shares traded on EURONEXT. Check live feeds for intraday moves.
What does Meyka AI forecast for PHARM.AS stock?
Meyka AI’s forecast model projects a 12-month price of €1.93, implying 20.48% upside from €1.60. Forecasts are model-based projections and are not guarantees.
What are the main risks for PHARM.AS stock?
Key risks include clinical trial setbacks, regulatory delays, pricing pressure for Ruconest, and stretched valuation given near-zero earnings. A negative earnings surprise could press the price below key support levels.
How does PHARM.AS stock compare to its sector?
PHARM.AS trades at higher P/S and P/B ratios than many small biotech peers but lacks stable earnings. The Healthcare sector average P/E is around 35.38, while Pharming’s earnings profile keeps its effective PE metrics distorted.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
